Ana Oaknin
安娜·奥克宁
MD, PhD
Head of Gynecologic Cancer Program妇科肿瘤项目负责人
👥Biography 个人简介
Dr. Ana Oaknin leads the Gynecologic Cancer Program at Vall d'Hebron, Barcelona. A principal investigator for KEYNOTE-826, she established pembrolizumab plus chemotherapy as the new standard of care for persistent/recurrent/metastatic cervical cancer, transforming outcomes globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Cervical Cancer Immunotherapy
Served as lead investigator on KEYNOTE-826, demonstrating pembrolizumab plus chemotherapy significantly improved OS and PFS in advanced cervical cancer with PD-L1 expression.
Endometrial Cancer Treatment
Contributed to studies evaluating immunotherapy combinations in mismatch repair-deficient endometrial cancer, advancing precision treatment approaches in Europe.
Representative Works 代表性著作
Pembrolizumab plus Chemotherapy for Advanced Cervical Cancer (KEYNOTE-826)
New England Journal of Medicine (2022)
Established pembrolizumab plus chemotherapy as standard first-line treatment for PD-L1-positive advanced cervical cancer.
Dostarlimab in Recurrent Endometrial Cancer (GARNET)
Lancet Oncology (2021)
Demonstrated high response rates with dostarlimab in mismatch repair-deficient recurrent endometrial cancer.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Bradley J. Monk
University of Arizona / HonorHealth
Kathleen N. Moore
Stephenson Cancer Center, University of Oklahoma
Shannon Neville Westin
The University of Texas MD Anderson Cancer Center
Vicky Makker
Memorial Sloan Kettering Cancer Center
关注 安娜·奥克宁 的研究动态
Follow Ana Oaknin's research updates
留下邮箱，当我们发布与 Ana Oaknin（Vall d'Hebron University Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment